Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods …

Background Icotinib, an oral EGFR tyrosine kinase inhibitor, had shown antitumour activity
and favourable toxicity in early-phase clinical trials. We aimed to investigate whether icotinib …

Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-
driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor …

Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be
reviewed, both in patients who have previously failed chemotherapy and in the first-line …

The ɛ4 allele of the apolipoprotein E (APOE) gene is currently the strongest and most highly
replicated genetic factor for risk and age of onset of late-onset Alzheimer's disease (LOAD) …

Background A fusion gene between echinoderm microtubule-associated protein-like 4
(EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small …

HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic
materials into the targeted cells among many viral vectors. Genetic material transduced by …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …

Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …